PARIS (Reuters) - Swiss drugmaker Roche Holding AG
"It doesn't matter whether this is a medicine in primary care or whether this is a specialist medicine, it doesn't matter whether it's for small patient populations or for big populations," Schwan told a news conference in Paris.
"It is a matter of how much additional value you van generate, how much of an additional medical benefit you can generate for the individual patient and that is the criteria."
Asked if that meant he did not exclude a move into rare diseases, Schwan said: "We go where the science takes us - independent from the size or the patient population."
He declined to comment specifically on whether the company was interested in buying Alexion Pharmaceuticals or BioMarin
(Reporting by Natalie Huet. Writing by Caroline Copley;Editing by Erica Billingham)
- Europe News
- Health Care Industry
- Severin Schwan
- Roche Holding AG
Similar Articles: fox news kaley cuoco suntrust 2013 Emmy Winners "i Have A Dream" Speech
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.